Phospho-Met (Tyr1349) Recombinant Rabbit mAb (S-3345)

Phospho-Met (Tyr1349) refers to a critical phosphorylation modification at the C-terminal multifunctional docking site of the hepatocyte growth factor receptor (MET, a receptor tyrosine kinase), specifically the phosphorylation of tyrosine residue 1349. Upon binding of hepatocyte growth factor (HGF) to MET, MET dimerizes and undergoes autophosphorylation; once phosphorylated, Tyr1349 forms a stable characteristic "pYXNXXV" motif, acting directly as a high-affinity docking site for multiple downstream signaling effector proteins (such as GAB1, GRB2, SHC, and the p85 subunit of PI3K). This phosphorylation event serves as a central hub for activating several key signaling pathways, including Ras-MAPK (promoting cell proliferation), PI3K-Akt (promoting cell survival and migration), and PLCγ-Ca²⁺ (regulating cell morphology). Physiologically, it precisely regulates embryonic development, tissue regeneration, and synaptogenesis. Pathologically, hyperphosphorylation or sustained activation of Tyr1349 is commonly observed in various cancers (e.g., non-small cell lung cancer, gastric cancer, and colorectal cancer), driving aggressive tumor growth, epithelial-mesenchymal transition (EMT), and drug resistance through the recruitment of adaptor proteins such as GAB1.